Northern Trust Corp lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,252,341 shares of the biopharmaceutical company’s stock after selling 77,290 shares during the period. Northern Trust Corp owned 1.21% of Catalyst Pharmaceuticals worth $4,184,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the business. Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals by 6.0% in the 4th quarter. Rhumbline Advisers now owns 126,286 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 7,130 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Alliancebernstein L.P. now owns 156,787 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 7,987 shares during the period. ProShare Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 80.7% in the fourth quarter. ProShare Advisors LLC now owns 21,506 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 9,606 shares during the period. LPL Financial LLC bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $30,000. Finally, Strs Ohio grew its position in shares of Catalyst Pharmaceuticals by 7.2% during the 4th quarter. Strs Ohio now owns 179,800 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 12,100 shares during the period. Institutional investors own 64.86% of the company’s stock.
CPRX stock opened at $4.38 on Wednesday. The business’s 50-day moving average price is $4.15 and its two-hundred day moving average price is $3.67. The firm has a market cap of $454.75 million, a PE ratio of 6.54 and a beta of 1.53. Catalyst Pharmaceuticals, Inc. has a 1-year low of $2.88 and a 1-year high of $5.19.
Several research analysts recently weighed in on the stock. TheStreet raised shares of Catalyst Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Thursday, February 18th. Roth Capital lifted their price target on shares of Catalyst Pharmaceuticals from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, March 24th. Four analysts have rated the stock with a buy rating, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $7.63.
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
Recommended Story: What is the formula for the cash asset ratio?
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.